secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001933414-23-000085
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys Q3 net loss $22.8M; cash $265.9M; Phase 3 Launch-HTN start on track for 2H2023, topline delayed to 2H2025
--------------------------------------------------------------------------------

- Net loss $22.8M (Q3 2023) vs $6.7M (Q3 2022); R&D expenses $22.5M, up from $6.1M.
- Cash, cash equivalents and investments $265.9M as of Sep 30, 2023; expected to fund operations through mid-2025.
- Advance-HTN topline data revised from 1H2024 to 2H2024 due to protocol amendment and enrollment curve.
- Phase 3 Launch-HTN trial remains on track to initiate in 2H2023; topline data now expected in 2H2025.
- Explore-CKD Phase 2 trial expected to start in 2H2023 with topline data in Q4 2024–Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341423000085/0001933414-23-000085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341423000085/mlys-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001933414-23-000085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer